Plain-English translation of NCT07604987 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach called —a combination of five medications (rituximab, pirtobrutinib, methotrexate, dexamethasone, and thiotepa)—for people who have just been diagnosed with primary central nervous system lymphoma, a type of cancer that affects the brain. The goal is to see how well this medication combination works and how safe it is for patients with this condition.
Primary central nervous system lymphoma is a serious cancer affecting the brain that is difficult to treat. This trial exists because researchers want to test whether this new combination of medications can help more patients achieve remission and survive longer than existing treatment options.
You likely qualify if…
You likely don't qualify if…
You would receive six cycles of treatment over several months. Each cycle involves receiving four intravenous medications on different days (rituximab, methotrexate, dexamethasone, and thiotepa) and taking an oral medication at home for about three weeks. After finishing the six cycles, your doctor may recommend additional treatment such as stem cell transplant, radiation, or continued medication, depending on how well you respond. You'll have blood tests and imaging scans to monitor your progress.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
China